Novartis has appointed Page Bouchard, an industry veteran, to the role of chief scientific officer at AveXis Inc, a subsidiary at the center of a controversy over data manipulation in relation to the recently approved gene therapy Zolgensma for spinal muscular atrophy (SMA). Dr Bouchard has been with Novartis for 10 years and will take over the roles of CSO and head of research and development at AveXis that were previously held by Brian Kaspar and Allan Kaspar.
